Fangwen Zou
- Health Informatics top 10%
-
- Cancer Immunotherapy and Biomarkers 9
- Cancer Diagnosis and Treatment 3
- Vascular Tumors and Angiosarcomas 2
-
- Immune Cell Function and Interaction 3
-
- Microscopic Colitis 7
-
- Inflammatory Bowel Disease 5
-
- Circular RNAs in diseases 4
-
- Genetic factors in colorectal cancer 2
- Co-authors
- Anusha Shirwaikar ThomasYinghong WangChunhong HuIsabella C. Glitza OlivaJinan MaJohn A. ThompsonJennifer L. McQuadeHao Chi Zhang
- Journals
- Journal of Clinical Oncology (1 paper)Gastroenterology (3 papers)Scientific Reports (1 paper)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Fangwen Zou
25 papers receiving 341 citations
Peers
Comparison fields: 5 of 63
- Health Informatics 12
- Oncology 214
- Cancer Research 60
- Gastroenterology 12
- Immunology 45
Countries citing papers authored by Fangwen Zou
This map shows the geographic impact of Fangwen Zou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fangwen Zou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fangwen Zou more than expected).
Fields of papers citing papers by Fangwen Zou
This network shows the impact of papers produced by Fangwen Zou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fangwen Zou. The network helps show where Fangwen Zou may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Fangwen Zou, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 4 | |
| 2 | 2024 | 17 | |
| 3 | 2023 | 17 | |
| 4 | 2022 | 9 | |
| 5 | 2021 | 25 | |
| 6 | 2021 | 4 | |
| 7 | 2021 | 10 | |
| 8 | 2021 | 1 | |
| 9 | 2021 | 24 | |
| 10 | 2020 | 12 | |
| 11 | 2020 | 25 | |
| 12 | 2020 | 2 | |
| 13 | 2020 | 1 | |
| 14 | 2020 | 5 | |
| 15 | Decitabine reverses gefitinib resistance in PC9 lung adenocarcinoma cells by demethylation of RASSF1A and GADD45β promoter. | 2019 | 14 |
| 16 | 2017 | 2 | |
| 17 | 2015 | 17 | |
| 18 | 2014 | 6 | |
| 19 | 2014 | 2 | |
| 20 | 2013 | 1 |
About Fangwen Zou
Fangwen Zou is a scholar working on Health Informatics, Oncology and Epidemiology, having authored 25 papers that have together received 344 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), Microscopic Colitis (7 papers), Inflammatory Bowel Disease (5 papers), Circular RNAs in diseases (4 papers), Immune Cell Function and Interaction (3 papers), Cancer Diagnosis and Treatment (3 papers), Vascular Tumors and Angiosarcomas (2 papers) and Genetic factors in colorectal cancer (2 papers). The work is most often cited by research in Health Informatics (12 citations), Oncology (214 citations) and Cancer Research (60 citations). Fangwen Zou has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Anusha Shirwaikar Thomas, Yinghong Wang, Chunhong Hu, Isabella C. Glitza Oliva, Jinan Ma, John A. Thompson, Jennifer L. McQuade, Hao Chi Zhang, Xuemei Wang and Chaoyuan Liu. Their work appears in journals such as Journal of Clinical Oncology, Gastroenterology and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.